Provided by Tiger Fintech (Singapore) Pte. Ltd.

ArTara Therapeutics, Inc.

4.21
+0.01000.24%
Volume:139.17K
Turnover:585.66K
Market Cap:154.79M
PE:-1.94
High:4.28
Open:4.23
Low:4.13
Close:4.20
Loading ...

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

GlobeNewswire
·
23 Apr

Protara Therapeutics Initiated at Sector Outperform by Scotiabank

Dow Jones
·
16 Apr

Scotiabank Initiates Protara Therapeutics at Sector Outperform With $12 Price Target

MT Newswires Live
·
16 Apr

Protara Therapeutics Names Leonardo Viana Nicacio CMO

MT Newswires Live
·
16 Apr

Press Release: Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Dow Jones
·
16 Apr

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

GlobeNewswire
·
11 Apr

Protara Therapeutics’ TARA-002 Shows Promising Potential in NMIBC Treatment, Justifying Buy Rating

TIPRANKS
·
31 Mar

Protara Therapeutics: Dosing of First Patient in Thrive-3 Registrational Trial Expected in 1H 2025

THOMSON REUTERS
·
19 Mar

Protara Therapeutics Announces Encore Presentation of Results From Thrive-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

THOMSON REUTERS
·
19 Mar

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

GlobeNewswire
·
19 Mar

Cantor Fitzgerald Initiates Coverage on Protara Therapeutics With Overweight Rating

MT Newswires Live
·
14 Mar

Protara Therapeutics Initiated at Outperform by LifeSci Capital

Dow Jones
·
11 Mar

TD Cowen Keeps Their Buy Rating on Protara Therapeutics (TARA)

TIPRANKS
·
07 Mar

Protara Therapeutics’ TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating

TIPRANKS
·
06 Mar

Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
06 Mar

Protara Therapeutics Q4 EPS $(0.48) Beats $(0.56) Estimate

Benzinga
·
05 Mar

BRIEF-Protara Therapeutics Q4 EPS USD -0.48

Reuters
·
05 Mar

Protara Therapeutics: Cash, Cash Equivalents & Investments as of Dec 31, 2024 Expected to Support Planned Operations Into 2027

THOMSON REUTERS
·
05 Mar

Protara Therapeutics Q4 Net Income USD -12.769 Million

THOMSON REUTERS
·
05 Mar

Protara Therapeutics Q4 Operating Expenses USD 14.312 Million

THOMSON REUTERS
·
05 Mar